The TAILORx trial data presented by Dr. Virginia Kaklamani at SABCS highlights that anthracyclines are beneficial for patients with estrogen-positive early-stage breast cancer and a high genomic risk score, suggesting it may become a standard of care.
00:00 - Recurrence Score and Anthracycline Benefits
00:44 - High Genomic Risk Score and Standard of Care